期刊文献+

沙眼衣原体质粒蛋白pgp3多克隆抗体的制备及鉴定 被引量:4

Preparation and identification of polyclonal antibody against plasmid-encoded pgp3 protein of Chlamydia trachomatis
原文传递
导出
摘要 目的表达并纯化D型沙眼衣原体质粒蛋白pgp3,制备鼠源性多克隆抗体。方法诱导表达pgp3蛋白,经谷胱甘肽-S-转移酶(GST)磁珠纯化后免疫BALB/c小鼠,制备多克隆抗体,Western印迹、细胞免疫荧光鉴定抗体的特异性,间接ELISA法测定抗体效价。结果得到纯化的pgp3蛋白,获得鼠源性多克隆抗体,经Western印迹和细胞免疫荧光鉴定抗体可特异性结合pgp3蛋白,ELISA测定所得抗体效价为1:819200。结论成功制备具有高效价、高特异性的抗pgp3多克隆抗体。 Objective To express and purify pgp3 protein of Chlamydia trachomatis serovar D and prepare mouse anti-pgp3 polyclonal antibody. Methods The pgp3 protein was induced to be expressed and purified by glutathione S-transferase (GST) Magbeads. Then the purified pgp3 was injected into BALB/c mice to prepare polyclonal antibody. Western blot and immunofluorescence were used to identify the specificity of the antibody. The titer of the antibody was tested by indirect enzymeqinked immunosorbent assay (ELISA). Results The pgp3 protein was successfully expressed and purified. The mouse anti-pgp3 polyclonal antibody was prepared. Results of Western blot and immunofluorescence indicated that it was able to specifically bind to the pgp3 protein. The titer of the polyclonal antibody was 1 ." 819 200 which was tested by ELISA. Conclusion The anti-pgp3 polyclonal antibody with high specificity and high titer is successfully obtained, which could be useful to the researches on pathogenicity of Chlamydia trachomatis.
出处 《中华传染病杂志》 CAS CSCD 北大核心 2014年第2期77-79,共3页 Chinese Journal of Infectious Diseases
基金 国家自然科学基金资助项目(31100138,30901460,30671879)
关键词 衣原体 沙眼 质粒 pgp3蛋白 衣原体 抗体 细菌 Chlamydia trachomatis Plasmids pgp3 Protein,chlamydia Antibodies, bacterial
  • 相关文献

参考文献4

二级参考文献57

  • 1周娜娜,齐蔓莉,刘全忠.沙眼衣原体的聚合酶链式反应-限制性内切酶片段长度多态性分型研究[J].天津医科大学学报,2006,12(4):575-576. 被引量:2
  • 2Dreses-Werringloer U, Padubrin I, Ktohler LL, et al. Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis. Antimicrob Agents Chemother, 2003, 47( 7 ): 2316-2318.
  • 3Xia M, Suchland R J, Carswell JA, et al. Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis. Antimicrob Agents Chemother, 2005, 49 (9): 974-976.
  • 4Kutlin A, Kohlhoff S, Roblin P, et al. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob Agents Chemother, 2005, 49( 3 ): 903-907.
  • 5Somani J, Bhullar VB, Workowski KA, et al. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis, 2000, 181(4): 1421-1427.
  • 6Demars R, Weinfurter J, Guex E, et al. Lateral gene transfer in vitro in the intracellular pathogen Chlamydia trachomatis. J Bacteriol, 2007, 189(3): 991-1003.
  • 7Homer P. The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infections. Sex Transm Infect,2006, 82(4): 340-343.
  • 8Zele-Starcevie L, Plecko V, Budimir A, et al. Choice of antimicrobial drug for infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae. Acta Med Croatica, 2004, 58(4): 329-333.
  • 9Low N, Cowan F. Genital chlamydial infection.Clin Evid, 2002, (8):1601-1607.
  • 10Samra Z, Rosenberg S, Soffer Y, et al.In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis, 2001 ,39 (3): 177-179.

共引文献25

同被引文献16

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部